Free Trial

ProQR Therapeutics (PRQR) Competitors

ProQR Therapeutics logo
$1.42 -0.02 (-1.05%)
As of 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PRQR vs. GHRS, VALN, TYRA, UPB, CGEM, OPT, AKBA, PGEN, ANAB, and MAZE

Should you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include GH Research (GHRS), Valneva (VALN), Tyra Biosciences (TYRA), Upstream Bio (UPB), Cullinan Therapeutics (CGEM), Opthea (OPT), Akebia Therapeutics (AKBA), Precigen (PGEN), AnaptysBio (ANAB), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry.

ProQR Therapeutics vs.

GH Research (NASDAQ:GHRS) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.

GH Research has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. GH Research's return on equity of -20.29% beat ProQR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
GH ResearchN/A -20.29% -19.49%
ProQR Therapeutics -134.31%-71.58%-19.70%

ProQR Therapeutics received 306 more outperform votes than GH Research when rated by MarketBeat users. However, 76.92% of users gave GH Research an outperform vote while only 61.99% of users gave ProQR Therapeutics an outperform vote.

CompanyUnderperformOutperform
GH ResearchOutperform Votes
30
76.92%
Underperform Votes
9
23.08%
ProQR TherapeuticsOutperform Votes
336
61.99%
Underperform Votes
206
38.01%

In the previous week, ProQR Therapeutics had 3 more articles in the media than GH Research. MarketBeat recorded 5 mentions for ProQR Therapeutics and 2 mentions for GH Research. ProQR Therapeutics' average media sentiment score of 1.35 beat GH Research's score of 0.94 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GH Research
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ProQR Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

GH Research presently has a consensus target price of $30.86, indicating a potential upside of 178.37%. ProQR Therapeutics has a consensus target price of $9.50, indicating a potential upside of 571.38%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than GH Research.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GH Research
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
ProQR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

ProQR Therapeutics has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GH ResearchN/AN/A-$35.59M-$0.75-14.78
ProQR Therapeutics$18.91M7.87-$30.43M-$0.34-4.16

GH Research has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.

56.9% of GH Research shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ProQR Therapeutics beats GH Research on 10 of the 18 factors compared between the two stocks.

Remove Ads
Get ProQR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRQR vs. The Competition

MetricProQR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$148.88M$6.93B$5.63B$7.83B
Dividend YieldN/A2.73%4.57%4.00%
P/E Ratio-4.427.1623.1218.67
Price / Sales7.87221.41388.1791.15
Price / CashN/A65.6738.1634.64
Price / Book2.576.386.884.23
Net Income-$30.43M$142.12M$3.20B$247.15M
7 Day Performance-14.24%-4.83%-2.86%-2.16%
1 Month Performance-39.27%-7.22%1.72%-5.71%
1 Year Performance-37.67%-8.75%9.77%-0.81%

ProQR Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRQR
ProQR Therapeutics
2.019 of 5 stars
$1.42
-1.0%
$9.50
+571.4%
-39.9%$148.88M$18.91M-4.42180Analyst Revision
Positive News
Gap Up
GHRS
GH Research
2.4758 of 5 stars
$10.65
-3.2%
$30.86
+189.7%
+14.4%$554.10MN/A-13.4810
VALN
Valneva
1.8345 of 5 stars
$6.81
+0.3%
$17.00
+149.6%
-8.9%$553.39M$158.54M-52.38700Short Interest ↑
TYRA
Tyra Biosciences
2.2125 of 5 stars
$10.74
-6.6%
$30.50
+184.0%
-40.7%$543.48MN/A-6.6720Earnings Report
Upcoming Earnings
Analyst Forecast
News Coverage
Gap Up
UPB
Upstream Bio
N/A$9.87
+2.7%
$56.50
+472.4%
N/A$529.44M$2.37M0.0038Positive News
CGEM
Cullinan Therapeutics
2.1781 of 5 stars
$9.03
+2.7%
$32.86
+263.9%
-53.2%$528.37MN/A-3.1830
OPT
Opthea
0.7069 of 5 stars
$3.41
+7.1%
$12.00
+252.4%
-12.8%$524.07M$87,666.000.008Analyst Downgrade
Short Interest ↑
Analyst Revision
News Coverage
Gap Up
AKBA
Akebia Therapeutics
3.5491 of 5 stars
$2.40
+6.2%
$6.75
+181.3%
-13.8%$523.63M$169.88M-10.43430
PGEN
Precigen
3.5697 of 5 stars
$1.78
-1.1%
$7.00
+293.3%
+13.1%$521.31M$3.96M-3.24190
ANAB
AnaptysBio
2.9926 of 5 stars
$16.51
-1.3%
$35.11
+112.7%
-12.8%$506.31M$91.28M-2.72100Buyback Announcement
High Trading Volume
MAZE
Maze Therapeutics
N/A$11.49
+4.5%
$25.67
+123.4%
N/A$503.00M$167.50M0.00121
Remove Ads

Related Companies and Tools


This page (NASDAQ:PRQR) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners